Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

R. L. Bromley, M. Bickle Graz, M. Bluett-Duncan, C. Chambers, P. Damkier, K. Dietrich, H. Dolk, K. Grant, S. Mattson, K. J. Meador, H. Nordeng, T. F. Oberlander, A. Ornoy, A. Revet, J. Richardson, J. Rovet, L. Schuler-Faccini, E. Smearman, V. Simms, C. VorheesK. Wide, A. Wood, L. Yates, E. Ystrom, T. A. Supraja, J. Adams

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
31 Downloads (Pure)

Abstract

Background: Exposure in utero to certain medications can disrupt processes of fetal development, including brain development, leading to a continuum of neurodevelopmental difficulties. Recognizing the deficiency of neurodevelopmental investigations within pregnancy pharmacovigilance, an international Neurodevelopmental Expert Working Group was convened to achieve consensus regarding the core neurodevelopmental outcomes, optimization of methodological approaches and barriers to conducting pregnancy pharmacovigilance studies with neurodevelopmental outcomes. Methods: A modified Delphi study was undertaken based on stakeholder and expert input. Stakeholders (patient, pharmaceutical, academic and regulatory) were invited to define topics, pertaining to neurodevelopmental investigations in medication-exposed pregnancies. Experts were identified for their experience regarding neurodevelopmental outcomes following medicinal, substances of misuse or environmental exposures in utero. Two questionnaire rounds and a virtual discussion meeting were used to explore expert opinion on the topics identified by the stakeholders. Results: Twenty-five experts, from 13 countries and professionally diverse backgrounds took part in the development of 11 recommendations. The recommendations focus on the importance of neurodevelopment as a core feature of pregnancy pharmacovigilance, the timing of study initiation and a core set of distinct but interrelated neurodevelopmental skills or diagnoses which require investigation. Studies should start in infancy with an extended period of investigation into adolescence, with more frequent sampling during rapid periods of development. Additionally, recommendations are made regarding optimal approach to neurodevelopmental outcome measurement, comparator groups, exposure factors, a core set of confounding and mediating variables, attrition, reporting of results and the required improvements in funding for potential later emerging effects. Different study designs will be required depending on the specific neurodevelopmental outcome type under investigation and whether the medicine in question is newly approved or already in widespread use. Conclusion: An improved focus on neurodevelopmental outcomes is required within pregnancy pharmacovigilance. These expert recommendations should be met across a complementary set of studies which converge to form a comprehensive set of evidence regarding neurodevelopmental outcomes in pregnancy pharmacovigilance.
Original languageEnglish
Article number1094698
Pages (from-to)1-14
Number of pages14
JournalFrontiers in Pharmacology
Volume14
Early online date1 Jun 2023
DOIs
Publication statusPublished online - 1 Jun 2023

Bibliographical note

Funding Information:
This work has been completed as part of the ConcePTION study. The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA.

Publisher Copyright:
Copyright © 2023 Bromley, Bickle Graz, Bluett-Duncan, Chambers, Damkier, Dietrich, Dolk, Grant, Mattson, Meador, Nordeng, Oberlander, Ornoy, Revet, Richardson, Rovet, Schuler-Faccini, Smearman, Simms, Vorhees, Wide, Wood, Yates, Ystrom, Supraja and Adams.

Keywords

  • neurobehavior
  • teratogens
  • in utero exposure
  • neurodevelopment
  • pregnancy
  • pharmacovigilance
  • medicines

Fingerprint

Dive into the research topics of 'Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies'. Together they form a unique fingerprint.

Cite this